| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
The cost of healthcare in the U.S. is skyrocketing and employers and lawmakers must play a larger role to reduce the burden on Americans. So far, they aren’t doing enough, experts say. “Vitamin D screenings were in a typical bundle of laboratory services that are already provided,” she said. “[It’s] talking directly to LabCorp and Quest Diagnostics, saying ‘take this off your bundle, it’s no longer needed.’”
Marijuana may be legal now in Michigan, but many employees are likely to face strict workplace policies and still run the risk of being fired. That's partly because the federal government still considers marijuana to be a controlled substance. But whether they do business with Washington, employers face a legal landscape of complicated interactions with their workers. According to the 2017 annual report from Quest Diagnostics, two percent of the drug tests they analyzed nationally tested positive for marijuana.
While cities like New York have cracked down on CBD in food and drinks, that is not case in Kansas City. But how much of it people consume is important and could have an impact on whether or not they land their next job. However, lab-testing company, Quest Diagnostics, wrote in a blog post earlier this month:[CR-LF][CR-LF]"If the CBD product contains THC at a sufficiently high concentration, it is possible, depending on usage patterns, that the use of these products could cause a positive urine drug test result"
Transforming raw data into actionable information is crucial to the financial future of provider organizations, especially as pressure builds on providers to align their care delivery approach with value-based care and consumerism in healthcare. However, many providers lack the time and money to implement this critical function. Fortunately, the right technology can assist providers in getting the most out of their data while freeing up resources better used for patient care. A 2018 Quest Diagnostics survey of physicians and health plan executives found that providers do not have access to the tools they need to succeed under value-based arrangements. Providers still need EHRs, clinical decision support, data analytics, and EHR plug-ins or modules, as well as access to comprehensive patient data.
The American Diabetes Association (the Association) recently released a new economic report that details the fiscal impact of diabetes in the United States – and the results should alarm employers, benefit managers, and HR executives. According to the Association, about 30.3 million people in the U.S. are living with diabetes. In 2017, the total estimated costs associated with diagnosed diabetes were a staggering $327 billion, an increase of 26 percent compared to 2012. About one-third of this cost -- $109 billion -- is due to medical costs to care for patients with diabetes. Another $30 billion is due to indirect costs in the employed population, including increased absenteeism and reduced productivity.
A growing number of employers are adopting workplace wellness programs to improve employee health and subsequently lower their health insurance spend. As they do, benefit managers are tasked with vetting options that will deliver meaningful health and financial results for their companies.A study published in the peer-reviewed journal PLoS ONE, for instance, found that one in three first-time participants in a company-sponsored, lab-based wellness program by Quest Diagnostics were not aware they were at risk for a serious medical condition, such as diabetes or heart disease, according to biometric screening results.
Quest Diagnostics announced today that it will provide full laboratory management services for Georgia-based Houston Medical Center and Perry Hospital. Under the agreement, Quest will provide management expertise, lab equipment, supplies, and procurement processes to the two hospitals. It will also perform reference testing to them. Other terms of the deal were not disclosed.
Quest Diagnostics, the world`s leading provider of diagnostic information services, today announced that its Board of Directors has elected Denise M. Morrison to serve as a director, effective February 18, 2019. Including Ms. Morrison, the company`s Board has 11 members.
Quest Diagnostics Inc. this week named a chief information and digital officer, combining two enterprise technology roles, as digital tools continue to expand beyond providing back-room business support and into strategic data management and analytics. Gabrielle Wolfson, a former Xerox Corp. chief information officer, took on the dual role earlier this month at the medical diagnostic-information provider known for blood work, urinalysis and other laboratory tests, a company spokesperson said.
Quest Diagnostics has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories; BBPL’s anatomic pathology division, long-term care division, and Boyce and Bynum Pathology Professional Services are not part of the transaction. Through a separate professional services agreement, BBPPS will become the exclusive pathology provider for Quest clients in Missouri and a preferred pathology provider in the greater Midwestern region. The professional services agreement will go into effect at the time the acquisition is completed, which is expected in the first quarter of 2019.
Quest Diagnostics named Gabrielle Wolfson, a veteran IT business leader, as the company's new senior vice president and chief information and digital officer.
Quest Diagnostics saw fourth-quarter 2018 revenues of $1.84 billion and net income of $127 million. The company should grow by 2% this year, driven by acquisitions, said CEO Steve Rusckowski.
As fentanyl comes and goes in the news, it still remains a serious drug in America. Fentanyl is highly addictive synthetic opioid 50 to 100 times more potent than morphine and 50 times more potent than many forms of heroin. The pharmaceutical drug is manufactured for pain management; however clandestine laboratories also produce the drug and mix in heroin. Sometimes referred to as Apace, China Girl, Dance Fever, or He-Man, the deadly cocktail has infiltrated our streets, neighborhoods, and workplaces.
Quest Diagnostics announced this week that is has completed its previously announced acquisition of the clinical lab services assets of Boyce and Bynum Pathology Laboratories (BBPL). Through a separate professional services agreement, Boyce and Bynum Pathology Professional Services is now the exclusive pathology provider for Quest clients in Missouri, and a preferred pathology provider in the greater Midwest.
Have you heard of cannabidiol (CBD oil)? It's growing in popularity as a natural way to treat epileptic seizures. And more broadly, anxiety and insomnia. The issue is how close CBD is, scientifically, to marijuana.[CR-LF][CR-LF]Marijuana is rich in the compound THC, which gets you high. And while CBD is not pot it does have a tiny bit of THC in it. That has some people wondering if CBD oil can cause someone to fail a drug test. For answers, I'm looking at what federal law says about CBD and I'm reaching out to one of the largest lab-testing companies in America: Quest Diagnostics. Dr. Barry Sample is Quest's director of science and technology. And yes, that's really his name.
Quest Diagnostics today reported a 1 percent year-over-year drop in revenues for the fourth quarter, missing the consensus analyst expectation. Revenue for the three months ended Dec. 31, 2018 was $1.84 billion, down from $1.87 billion in the same quarter last year. The consensus Wall Street estimate was $1.88 billion.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2018. "In 2018 we grew revenues, adjusted earnings and cash from operations despite some challenges in the marketplace. Quest is well positioned once again in 2019 to deliver on our commitment to grow revenues and earnings, as our in-network status now extends to approximately 90% of commercially insured lives in the U.S.," said Steve Rusckowski, Chairman, CEO and President. "Our guidance for 2019 reflects significant reimbursement pressure offset by strong volume growth and continued execution of our Invigorate program. I am pleased to report our volumes for the year are off to a good start."
Ms. Wolfson is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. These include the company’s Quanum™ suite of healthcare IT solutions and data analytics, myQuest patient mobile app and portal, and digital engagement for the company’s 2,200 patient service centers.
Quest Diagnostics: Q4 Non-GAAP EPS of $1.36 misses by $0.01; GAAP EPS of $0.92 misses by $0.27.
Quest Diagnostics, the world's leading provider of diagnostic information services, and Houston Healthcare are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through a new partnership agreement under which Quest will provide full laboratory management services for Houston Medical Center and Perry Hospital.
Secaucus-based Quest Diagnostics announced Monday it has completed its previously announced acquisition of the clinical laboratory services business of Boyce & Bynum Pathology Laboratories. BBPL, based in Columbia, Missouri, is a provider of diagnostic and clinical laboratory services in the Midwest. Through a separate agreement, BBPL has been named the exclusive pathology provider for Quest Diagnostic clients in Missouri.
IBM Watson Health today announced an expansion to its partnership with the Broad Institute, providing artificial intelligence to help clinicians mine genomic data to predict patient risk for cardiovascular disease. IBM Watson and the Broad already are a little more than two years into a five-year, $50 million research initiative that seeks to discover the basis for drug resistance in cancers. The Broad is a partner in IBM Watson Genomics from Quest Diagnostics, a service that is available to oncologists nationwide that focuses on oncology diagnostics and providing options for evidence-based methods of treating cancer.
The stigma around marijuana use, both medical and recreational, is slowly dwindling as states throughout the country work towards marijuana legalization. 33 states have officially declared medical marijuana use legal and 10 states have legalized recreational use of the drug. However, a question lingers nationwide regarding views of marijuana in the workplace. All companies hold the right to drug test their employees; however, some industries feel that it’s necessary to test for marijuana regularly while others don’t. On the flip side, there is a large number of companies that don’t drug test as heavily — and that number is growing. With drug tests costing companies around $30 to $50 per employee, many see it as a wasted expense. Quest Diagnostics said that failed drug tests reached an all-time high in 2017 and this is likely to increase as legalization becomes more widespread. Drug testing restricts the job pool, meaning companies aren’t able to find the best candidates for open positions.
The most recent short interest data has been released for the 01/31/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded.
Quest Diagnostics, the world's leading provider of diagnostic information services, announced that it has completed its previously announced acquisition of the clinical laboratory services business of Boyce & Bynum Pathology Laboratories (BBPL), a leading provider of diagnostic and clinical laboratory services in the Midwest.